Eli Lilly’s decision to adopt Veeva Systems (VEEV) Vault CRM globally, combined with an upcoming leadership change in sales and services, gives investors new context for thinking about the stock’s current positioning.

The Eli Lilly agreement and leadership change arrive as Veeva Systems’s 30 day share price return of 34.33% and 90 day share price return of 54.77% contrast with a 1 year total shareholder return that declined 14.77%. This suggests momentum has recently rebuilt after a weaker year.

If you are looking beyond Veeva Systems in healthcare technology, this is a useful moment to scan the market for other AI driven health names using the 41 healthcare AI stocks

After a sharp rebound in Veeva Systems’s share price and a fresh vote of confidence from Eli Lilly, the next issue is whether most of the upside has already played out or whether current valuation still leaves meaningful room ahead.

Most Popular Narrative: 22.5% Undervalued

The current Veeva Systems share price of $247.90 sits below the narrative fair value of $320. This gap is what the widely followed thesis is trying to explain.

Veeva is best understood as a high-quality compounding business whose long-term value may be driven less by dramatic quarterly surprises and more by the gradual deepening of its role as the operating system for life sciences.

The key is patience and valuation discipline.

Want to see how that $320 figure is built? According to John_Eric the narrative leans heavily on robust margins, resilient recurring revenue, and disciplined growth assumptions. Curious which specific cash flow and growth trajectories support that valuation gap?

Result: Fair Value of $320 (UNDERVALUED)

However, Veeva Systems still faces real risks, including weaker pharmaceutical tech spending after mergers and the chance that Falcon adoption or pricing falls short of investor expectations.

Next Steps

Given the mix of optimism and caution around Veeva Systems, it makes sense to move quickly and test the thesis against your own research. To see which rewards other investors are focused on, review the 3 key rewards

Looking for more investment ideas beyond Veeva Systems?

If you want to keep building on the work you have already done on Veeva Systems, you can use the Simply Wall Street Screener to source additional stock ideas.

• Review companies highlighted in the 48 high quality undervalued stocks to explore potential value opportunities.
• Scan stocks featured in the 78 resilient stocks with low risk scores to focus on resilience.
• Check the screener containing 19 high quality undiscovered gems to explore underfollowed opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.